secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sonnet BioTherapeutics Holdings, Inc. (—)
CIK:        0001106838
Form:       8-K
Filed at:   2024-05-03T23:59:59+00:00
Accession:  0001493152-24-017629
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sonnet enters $25M ChEF equity facility with Chardan; 4% VWAP discount, 36-month term
--------------------------------------------------------------------------------

- Up to $25M aggregate gross purchase price of common stock under ChEF Purchase Agreement with Chardan Capital Markets.
- Shares sold at a fixed 4.0% discount to VWAP; Company controls timing and amount of draws.
- 36-month investment period; $100K initial + $150K six-month commitment fees; Exchange Cap of 622,168 shares (19.99% of outstanding).
- Proceeds for R&D, clinical trials, working capital; no short sale or hedging by Chardan prior to agreement.
- Company may terminate at any time after commencement with 10 trading days' notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1106838/000149315224017629/0001493152-24-017629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1106838/000149315224017629/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-017629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer